Propeller Health announced today it will begin distributing in Japan through collaboration with Novartis by connecting Propeller’s digital health platform to two of Novartis’ medications. 

According to a release, Enerzair Breezhaler was approved in Japan on June 29 for the treatment of bronchial asthma, and Atectura Breezhaler was approved as a LABA/ICS combination asthma treatment. Patients using both will now have access to Propeller’s digital health platform through their clinician.

“We are thrilled to bring the Propeller platform to Japan and introduce digital health for asthma to a large population of patients who can benefit from better management,” Propeller Health CEO David Van Sickle said in a statement. “This collaboration is an important step in improving outcomes for people with chronic respiratory disease worldwide.”

The Propeller platform also is used by patients in Europe.